Kristian Flaten, CFO in IDEX Biometrics ASA, has today bought 1,000,000 shares in IDEX Biometrics ASA, at an average price of NOK 0.1180 per share. After this transaction, Flaten owns 1,000,000 shares in IDEX Biometrics ASA. Please refer to the attached notification of trading for further details. For further information contact:Marianne Bøe, Head of Investor RelationsKristian Flaten, CFOE-mail: ir@idexbiometrics.comTel: + 47 67 83 91 19 About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX) is a global techn ...

Core Points - IDEX Biometrics ASA is conducting a subsequent offering of up to 140 million shares at NOK 0.15 per share following a private placement on 16 September 2024 [1] - Shareholders who held shares on 16 September 2024 and did not participate in the private placement can subscribe to this offering [2] - The subscription deadline is set for 29 November 2024 at 16:30 CET [2] Subscription Details - Shareholders will receive 0.5485 subscription rights per share held as of the record date [3] - The subscription price is NOK 0.15 per share, and for every two shares subscribed, shareholders will receive two additional warrants at the same exercise price [3] - Oversubscription is permitted, and further details can be found in the prospectus and subscription form [3] Company Overview - IDEX Biometrics ASA is a global leader in fingerprint biometrics, providing authentication solutions for payments, access control, and digital identity [4] - The company's biometric solutions are based on patented sensor technologies and target card-based applications for payments and digital authentication [4] - IDEX partners with leading card manufacturers and technology companies to bring its solutions to market [4]

Oslo, Norway, and Seoul, South Korea 19 November 2024 – IDEX Biometrics has entered into a commercial development agreement with South Korean smart card manufacturer Cellfie Global (formerly ICK) to design, manufacture and market biometric metal and PVC cards for bank and fintech launches in USA, Europe and Asia. This gives IDEX Biometrics full coverage across all four card manufacturers in South Korea, representing a production capacity in excess of 100 million smart cards annually, and with world leading ...

Reference is made to the stock exchange announcement issued by IDEX Biometrics ASA (the “Company”) on 17 September 2024 regarding the successful private placement of 466,666,666 new shares (“Private Placement” and the “Private Placement Shares”), and the possible subsequent offering of up to 140,000,000 new shares (“Subsequent Offering” and the “Subsequent Offering Shares”). As stated in the announcement on 17 September 2024, the listing of the Private Placement Shares and the offering and listing of the Su ...

Financial Performance - Sales for Q3 2024 were $798 million, a 1% increase overall, with organic sales remaining flat[1] - Reported diluted EPS was $1.57, down 43%, while adjusted diluted EPS was $1.90, down 10%[1] - Full year GAAP diluted EPS guidance is revised to $6.65 - $6.70, down from $6.85 - $6.95[1] - Net income attributable to IDEX for Q3 2024 was $119.1 million, down from $209.1 million in Q3 2023, representing a 43% decrease year-over-year[14] - Basic earnings per share attributable to IDEX for Q3 2024 were $1.57, compared to $2.76 in Q3 2023, reflecting a significant decline in earnings[14] - Adjusted net income attributable to IDEX for the nine months ended September 30, 2024, was $443.4 million, down from $484.6 million in the same period of 2023[23] - Reported net income for the three months ended September 30, 2024, was $118.9 million, compared to $209.0 million for the same period in 2023, reflecting a decrease of 43.0%[24] Cash Flow and Liquidity - Operating cash flow decreased by 9% to $205 million, representing 172% of net income, up from 108%[1] - Free cash flow was $192 million, down 7%, and accounted for 133% of adjusted net income, up from 129%[1] - Cash and cash equivalents rose to $633.2 million as of September 30, 2024, compared to $534.3 million at the end of 2023, indicating improved liquidity[15] - Net cash flows provided by operating activities for the nine months ended September 30, 2024, were $495.5 million, slightly down from $515.7 million in the same period last year[16] - Free cash flow for the three months ended September 30, 2024, was $191.6 million, compared to $206.5 million in the same period last year, a decrease of 7.3%[25] - Operating cash flow conversion for the nine months ended September 30, 2024, was 130%, compared to 106% in the prior year[25] Sales and Revenue Trends - Full year 2024 organic sales growth is projected to decline by 1% to 2% compared to the previous year[1] - The Health & Science Technologies segment experienced a 5% decline in organic net sales due to lower volumes[6] - The Fire & Safety/Diversified Products segment reported a 4% increase in both reported and organic net sales[7] - Organic net sales for IDEX decreased by 1% for the nine months ended September 30, 2024, compared to a decrease of 3% for the same period in 2023[21] - The company expects a change in organic net sales of 3% to 4% for the fourth quarter of 2024, after accounting for acquisitions and foreign currency impacts[26] Asset and Liabilities - Total assets increased to $6,967.5 million as of September 30, 2024, up from $5,865.2 million at the end of 2023, driven by higher goodwill and cash reserves[15] - Long-term borrowings increased to $2,075.1 million as of September 30, 2024, compared to $1,325.1 million at the end of 2023, indicating increased leverage[15] Profitability Metrics - Adjusted EBITDA margin for Q3 2024 decreased to 26.9%, down 150 basis points from the previous year[3] - Operating income decreased to $168.0 million in Q3 2024 from $179.6 million in Q3 2023, reflecting a decline in profitability[14] - Adjusted EBITDA for the nine months ended September 30, 2024, was $646.8 million, down from $696.0 million in the prior year, representing a decline of 7.1%[24] - Adjusted EBITDA margin for the full year 2024 is expected to be between 26.9% and 27.0%[28] Acquisitions and Investments - The acquisition of Mott Corporation was completed on September 5, 2024, for a cash consideration of $986.2 million[8] - The company reported a net cash outflow from investing activities of $991.8 million for the nine months ended September 30, 2024, primarily due to acquisitions[16] Other Financial Metrics - Gross profit for Q3 2024 was $353.9 million, compared to $349.6 million in Q3 2023, indicating a gross margin improvement[14] - The gross margin for IDEX in the three months ended September 30, 2024, was 44.3%, slightly up from 44.1% in the same period of 2023[22] - The total depreciation expense for IDEX in the three months ended September 30, 2024, was $17.4 million, an increase from $14.7 million in the same period of 2023[17] - The total amortization of intangible assets for IDEX in the three months ended September 30, 2024, was $26.5 million, compared to $23.8 million in the same period of 2023[17] - The company experienced a fair value inventory step-up charge of $2.1 million for the three months ended September 30, 2024[23] - The company recorded a gain on the sale of business of $0.6 million during the three months ended September 30, 2024[29] Future Projections - Estimated diluted EPS attributable to IDEX for the full year 2024 is projected to be between $6.65 and $6.70[27] - Estimated net sales for the fourth quarter of 2024 are projected to be between $874.3 million and $882.3 million[28] - The impact from foreign currency on net sales is expected to be 1% for the fourth quarter of 2024[26]

IDEX Corporation's (IEX) third-quarter 2024 adjusted earnings of $1.90 per share surpassed the Zacks Consensus Estimate of $1.89. The bottom line decreased approximately 10.4% from the year-ago quarter's earnings of $2.12. However, it matched the upper band of the management's projected range of $1.85-$1.90 per share. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. IEX's Revenue Details IDEX's net sales of $798.2 million beat the Zacks Consensus Estimate of $791 million. The top li ...

For the quarter ended September 2024, Idex (IEX) reported revenue of $798.2 million, up 0.6% over the same period last year. EPS came in at $1.90, compared to $2.12 in the year-ago quarter. The reported revenue represents a surprise of +0.92% over the Zacks Consensus Estimate of $790.95 million. With the consensus EPS estimate being $1.89, the EPS surprise was +0.53%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expec ...

Company Performance - Idex reported quarterly earnings of $1.90 per share, exceeding the Zacks Consensus Estimate of $1.89 per share, but down from $2.12 per share a year ago, representing an earnings surprise of 0.53% [1] - The company posted revenues of $798.2 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 0.92% and showing an increase from $793.4 million year-over-year [2] - Over the last four quarters, Idex has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Future Outlook - The current consensus EPS estimate for the coming quarter is $2.03 on revenues of $849.16 million, and for the current fiscal year, it is $7.88 on revenues of $3.25 billion [7] - The estimate revisions trend for Idex is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Manufacturing - General Industrial industry, to which Idex belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Idex's stock performance [5]

Oslo, Norway – 29 October 2024 - IDEX Biometrics ASA’s interim report for the third quarter is attached to this notice (link below). The interim report is also available on the IDEX Biometrics website: www.idexbiometrics.com/investors/interim-results/ A webcast presentation of the interim report will be held by Catharina Eklof, Chief Executive Officer, today at 09:00 CET. The webcast presentation is attached to this notice (link below), and can be viewed at the following link: https://idexbiometrics.video ...

IDEX Corporation (IEX) is scheduled to release third-quarter 2024 results on Oct. 29, after market close. The Zacks Consensus Estimate for earnings has remained steady in the past 60 days. The company has an impressive earnings surprise history, having outperformed the consensus estimate in each of the preceding four quarters, the average surprise being 5.9%. The consensus estimate for revenues is pegged at $791 million, indicating a decline of 0.3% from the prior-year quarter's figure. The consensus estima ...